CRISPR’s Epic Patent Fight Changed the Course of Biology
By Megan Molteni,
Wired
| 09. 11. 2018
AFTER THREE BITTER years and tens of millions of dollars in legal fees, the epic battle over who owns one of the most common methods for editing the DNA in any living thing is finally drawing to a close. On Monday, the US Court of Appeals for the Federal Circuit issued a decisive ruling on the rights to Crispr-Cas9 gene editing—awarding crucial intellectual property spoils to scientists at the Broad Institute of Cambridge, Massachusetts.
The fight for Crispr-Cas9—which divided the research community and triggered an uncomfortable discussion about science for personal profit versus public good—has dramatically shaped how biology research turns into real-world products. But its long-term legacy is not what happened in the courtroom, but what took place in the labs: A wealth of innovation that is now threatening to make Cas9 obsolete.
This latest legal decision, which upholds a 2017 ruling by the US Patent and Trademark Office, was an expected one, given how rarely such rulings are overturned. And it more or less seals defeat for researchers at the University of California Berkeley, who also have claims...
Related Articles
Flag of South Africa; design by Frederick Brownell,
image by WikimediaCommons users.
Public domain, via Wikimedia Commons
What is the legal status of heritable human genome editing (HHGE)? In 2020, a comprehensive policy analysis by Baylis, Darnovsky, Hasson, and Krahn documented that more than 70 countries and an international treaty prohibit it, and that no country explicitly permits it. Policies in some countries were non-existent, ambiguous, or subject to possible amendment, but the general rule remained, even after one...
By Bernice Lottering, Gene Online | 11.08.2024
South Africa’s updated health-research ethics guidelines, which now include heritable human genome editing, have sparked concern among scientists. The revisions, made in May but only recently gaining attention, outline protocols for modifying genetic material in sperm, eggs, or embryos—changes that...
By Jim Thomas, Scan the Horizon | 11.19.2024
It’s the wee hours of 2nd November 2024 in Cali, Colombia. In a large UN negotiating hall Colombian Environment Minister Susana Muhamed has slammed down the gavel on a decision that should send a jolt through the AI policy world. ...
By Ned Pagliarulo, BioPharmaDive | 11.05.2024
A medicine built around a more precise form of CRISPR gene editing appeared to work as designed in its first clinical trial test, developer Beam Therapeutics said Tuesday. But the death of a trial participant could renew concerns about an older...